SCHEMBL3537508

SCHEMBL3537508

CC1CCN(c2cc(N3CCN(S(C)(=O)=O)CC3)ccc2N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.55
GAA P10253 4/20 0.54
MAPT P10636 4/20 0.54
HTT P42858 3/20 0.54
KDM4E B2RXH2 3/20 0.54
MAPK1 P28482 2/20 0.54
RECQL P46063 1/20 0.54
PTK2B Q14289 1/20 0.54
LGMN Q99538 5/20 0.49
ALDH1A1 P00352 7/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
S100B P04271 1/20 0.49
PKM P14618 1/20 0.49
ALOX15 P16050 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
USP2 O75604 2/20 0.48
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537507 0.83 CSF1R (0.54) CSF1RGAAMAPTKDM4EMAPK1
SCHEMBL3538623 0.82 GAA (0.79) CSF1RGAAMAPTHTTKDM4E
SCHEMBL27691384 0.80 LGMN (0.55) CSF1RGAAMAPTHTTKDM4E
SCHEMBL3539723 0.80 LGMN (0.55) CSF1RGAAMAPTHTTKDM4E
SCHEMBL3958578 0.79 GAA (0.55) CSF1RGAAMAPTHTTKDM4E
SCHEMBL3540354 0.79 LGMN (0.77) CSF1RGAAMAPTHTTKDM4E
SCHEMBL6151800 0.76 GAA (0.59) GAAMAPTHTTKDM4EMAPK1
SCHEMBL14320505 0.76 GAA (0.59) GAAMAPTHTTKDM4EMAPK1
SCHEMBL3966409 0.76 GAA (0.56) CSF1RGAAMAPTHTTKDM4E
SCHEMBL3541321 0.75 GPR119 (0.53) GAAMAPTHTTKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES CSF1R 34/4885GAA 3696/4885MAPT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.